Purchase this article with an account.
M. S. Pfister, F. Rothweiler, J. Cinatl, F. Koch, M. Michaelis, M. Koss; Intravitreal Growth Factors in Combined Therapy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1918.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To determine the change of intravitreal VEGF A, monocytic adhesion protein = MCP, and IL-6 levels in ARMD, DME and CRVO.
Twenty patients (80.9 years, 11 male) with wet ARMD, 3 with DME (62.6 years, 3 male), and 3 with CRVO (65.3 years, 1 male) underwent 0.5 to 1ml core pars plana vitrectomy (cppV) with subsitutition of 1.5mg bevacizumab and 800µg dexamthasone as a first line combined treatment to treat ME. The levels of VEGF, IL-6, and MCP were examined with cytometric bead assay from the aspired vitreous specimen (T1). Retreatment was conducted on clinical relevant increase in CMT and BCVA decrease (T2).
Twenty specimen (10 pseudophakia) at T1 and twelve at T2 (27.7 weeks after T1) from ARMD patients yielded VEGF A levels of totally 10.1 pg/dl (T1=5.5; T2=17.7), Il-6 of 63.1 (62.7; 63.8), and MCP 886.9 (793.9;1041.8) . There was no statistic difference between pseudophakic or phakic patients. In DME VEGF A was 46.5, IL-6 23.6, and MCP 614.3 pg/dl. In CRVO VEGF A was 190.4, Il-6, 25.4, and MCP 612.5 pg/dl.
This PDF is available to Subscribers Only